PMID: 9421618Jan 9, 1998Paper

Factors involved in leukaemogenesis and haemopoiesis

Baillière's Clinical Haematology
A G ElefantyC G Begley

Abstract

This review describes the chromosomal abnormalities in T-cell acute lymphoblastic leukaemia (ALL) which result in the over-expression of the gene SCL, which encodes a helix-loop-helix transcription factor. Also described are how gene targeting studies have revealed a key role for SCL in normal haemopoiesis. Next, the BCR-ABL fusion protein, seen in chronic myeloid leukaemia (CML) and in some patients with ALL, is discussed. Finally, the involvement of members of the core-binding factor (CBF) gene family in leukaemogenesis are described. Members of this gene family are involved in the generation of fusion proteins as a result of t(8;21) and inv(16), the most common translocations associated with acute myeloid leukaemia (AML). They provide a useful model of the way in which aberrant transcriptional function, brought about through genetic alterations, can modify haemopoietic development.

References

Sep 18, 1992·Cell·C L SawyersO N Witte
Apr 9, 1992·Nature·A DagaF Calabi
Feb 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·C G BegleyN M Gough
Dec 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·H MiyoshiM Ohki
Feb 1, 1991·Molecular and Cellular Biology·L VarticovskiL C Cantley
May 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·T BoehmT H Rabbitts
Mar 15, 1990·Nature·N HeisterkampJ Groffen
Dec 1, 1990·Molecular and Cellular Biology·P D AplanI R Kirsch
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·C G BegleyI R Kirsch
Jul 1, 1989·Molecular and Cellular Biology·I K HariharanJ M Adams
Nov 12, 1985·Biochimica Et Biophysica Acta·J B Konopka, O N Witte
Dec 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·G Q Daley, D Baltimore
Dec 1, 1987·Baillière's Clinical Haematology·J Groffen, N Heisterkamp
Sep 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·J McLaughlinO N Witte
Feb 28, 1986·Cell·Y Ben-NeriahD Baltimore
Mar 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·J EriksonC M Croce

❮ Previous
Next ❯

Citations

Oct 17, 2001·Developmental and Comparative Immunology·D R Barreda, M Belosevic
Mar 20, 2004·Developmental Cell·Patricia ErnstStanley J Korsmeyer
Nov 12, 2016·Science China. Life Sciences·Xueping GongYuan Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.